Lumican was also found to be an endogenous inhibitor of TGF-β2 activity, resulting in downstream effector modulation, including pSmad 2, integrin β1, and pFAK, to regulate osteosarcoma adhesion [41]. Here, LUM is linked to osteosarcoma.